ERBB2 and breast carcinoma: To address this critical gap in knowledge, Paul et al. [3] recently performed whole exome and shallow whole genome sequencing of paired primary and recurrent breast cancers in patients in the METAMORPH study who had undergone anti-estrogen therapy, chemotherapy, and/or anti-HER2 therapy prior to tumor recurrence.